David Dodd/GeoVax
GeoVax Labs is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease program includes GEO-CM04S1, a next-generation Covid-19 vaccine designed for the growing population of high-risk immunocompromised patients with cancers, autoimmune conditions, and neuromuscular diseases. Currently in two Phase 2 clinical trials, CM04S1 is being evaluated as a Covid-19 vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized Covid-19 vaccines are insufficient. In addition, CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable Covid-19 booster among healthy patients who previously received the mRNA vaccines. A synergistic program is underway with the rights from the US NIH to make GeoVax the first U.S. supplier of the vaccine vector MVA for protection against Monkeypox and Smallpox. GEO-CM04S1 GeoVax has a solid financial foundation, is listed on Nasdaq (“GOVX”), with a leadership team who have driven significant value creation across multiple life science companies over the past several decades.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.